Expression of extracellular matrix proteins nidogen‐1 and legumain in endometrial carcinomas

Abstract

Purpose: Our purpose was to comparatively investigate the expressions of nidogen-1 (NID1) and legumain (LGMN) in patients with endometrial cancer, endometrial intraepithelial neoplasia, and proliferative endometrium. Methods: A cross-sectional, single-center study was performed by the obstetrics and gynecology and pathology departments of our institution. The relationships between descriptive data, clinicopathologic information, and immunohistochemical expressions of NID1 and LGMN were investigated. Results: The histological grades of endometrial cancers (n = 124) as classified by FIGO included 1 (41, 21.1%), 2 (48, 24.7%), and 3 (35, 18.0%). The medians and ranges of deep and superficial NID1 expressions were 50.00 (0-285) and 5.00 (0-100), respectively. The intensity of legumain expression was noted as negative (30, 24.2%), mild (16, 12.9%), moderate (27, 21.8%), or strong (51, 41.1%). Median disease-free survival and overall survival were 75.00 (range: 1 to 170) months and 77.00 (range: 1 to 170) months, respectively. Patients with more intense expression of NID1 and LGMN displayed a higher histological grade. These patients were more likely to have a positive peritoneal cytology, larger tumor size, higher tendency for myometrial or lymphovascular invasion, involvement of ovaries, cervix, omentum, as well as lymph node metastasis, and recurrence. Conclusion: Our data indicated that the expressions of NID1 and LGMN may have important diagnostic implications in endometrial pathologies. Further studies should be performed to understand the significance of NID1 and LGMN in the pathogenesis of endometrial tumors.

Screening and identification of key biomarkers associated with endometriosis using bioinformatics and next generation sequencing data analysis

“…A previous study reported that the L1CAM [386], HSD17B2 [387], GRP (gastrin releasing peptide) [388], FABP4 [389], SOX6 [390]. MMP12 [391], APOD (apolipoprotein D) [392], LAG3 [393], CST1 [394], FLT1 [395], DHCR24 [396], PRL (prolactin) [397], WNT5A [398], TIMP3 [399], CD24 [400], LHCGR (luteinizing hormone/choriogonadotropin receptor) [401], MMRN1 [402], CD4 [403], ADAMTS5 [404], ADAMTS1 [405], PADI2 [406], MARK1 [407], KL (klotho) [408], PLAU (plasminogen activator, urokinase) [409], SOX8 [410], CRABP2 [411], PTPRD (protein tyrosine phosphatase receptor type D) [412], EPCAM (epithelial cell adhesion molecule) [413], IRX2 [414], SEMA3B [415], CYP1A1 [416], PDGFD (platelet derived growth factor D) [417], LEPR (leptin receptor) [418], APOE (apolipoprotein E) [419], CASP1 [420], MGLL (monoglyceride lipase) [421], NID1 [422], ABCG2 [423], ACE (angiotensin I converting enzyme) [424], PGR (progesterone receptor) [425], HPSE2 [426], LMTK3 [427], ALPP (alkaline phosphatase, placental) [428], EGFL6 [429], CACNA2D3 [430], MCTP1 [431], HKDC1 [432], S100A4 [433], MACC1 [434], MMP3 [435], FGFR2 [436], IL33 [437], FOXC2 [438], ITGA7 [439], EFEMP1 [440], GATA6 [441], BHLHE41 [442], TCF21 [443], GDF10 [444], NKX3-1 [445], AKR1C3 [446], SGK1 [447], RAP1GAP [448], FLI1 [449], NOX4 [450], SERPINE2 [451], IGSF9 [452], IGF2BP1 [453], SALL4 [454], VDR (vitamin D receptor) [455], CELSR2 [456],...…”

The Lifestyle Modifications and Endometrial Proteome Changes of Women With Polycystic Ovary Syndrome and Obesity

“…In their very recent study, the authors investigated correlation of endometrial carcinoma to Legumain expression in human endometrium. Patients with higher Legumain expression were more likely to have higher carcinoma grade as well as carcinoma recurrence ( 38 ). Therefore, one could expect, that reducing the endometrial activity by losing weight and normalizing hormonal balance should result in down-regulation of Legumain expression in the endometrium, but our findings suggest just the opposite effect.…”